A Sector Transformed: How COVID-19 Permanently Rewrote the Rules of Medical PPE Procurement
There is a particular kind of institutional knowledge that only comes from surviving a crisis. American healthcare acquired a great deal of it between 2020 and 2022, much of it painful, some of it embarrassing, and all of it instructive. The personal protective equipment failures of the early pandemic — the N95 shortages, the counterfeit gowns, the improvised face shields fashioned from office supplies — were not merely logistical inconveniences. They were systemic failures with life-altering consequences for healthcare workers and patients alike.
Four years on, the healthcare sector has changed in meaningful ways. Certification standards have evolved. Domestic manufacturing has received unprecedented investment. Procurement professionals have developed a sophistication about supply chain risk that simply did not exist before 2020. But the transformation is uneven, and many facilities remain more vulnerable than their administrators recognize.
This analysis examines what has genuinely changed, what has not changed enough, and what healthcare facilities need to understand as they approach PPE procurement in 2024 and beyond.
The Pre-Pandemic Baseline: A System Built for Efficiency, Not Resilience
To appreciate the magnitude of the shift, it is worth briefly revisiting where the healthcare PPE system stood before the pandemic arrived.
For decades, American hospitals and health systems optimized their supply chains for efficiency and cost minimization. Just-in-time inventory models, consolidated group purchasing organizations, and heavy reliance on offshore manufacturing — predominantly from China — kept per-unit costs low and warehouse footprints small. The system worked well in normal conditions. It was not designed for abnormal ones.
When COVID-19 created simultaneous global demand for the same categories of PPE, the vulnerabilities of that architecture became immediately apparent. Facilities that had maintained three to five days of N95 inventory found themselves with none. Domestic manufacturing capacity was insufficient to compensate for disrupted imports. The Strategic National Stockpile, intended as a backstop for exactly this kind of emergency, was neither adequately stocked nor efficiently distributed.
The result was a public health crisis layered on top of a supply chain crisis, with frontline healthcare workers absorbing the consequences of both.
What Has Actually Changed: Standards and Certification
The pandemic generated significant regulatory and standards activity in the PPE space, some of which has produced durable changes and some of which remains in flux.
NIOSH and N95 oversight. The National Institute for Occupational Safety and Health, which certifies respiratory protective devices, faced enormous pressure during the pandemic as counterfeit and substandard products flooded the market under the cover of emergency authorization waivers. In the post-pandemic period, NIOSH has strengthened its monitoring and enforcement activities and improved public-facing tools that allow healthcare facilities to verify the certification status of specific respirator models. The NIOSH Certified Equipment List (CEL) and the associated approval number verification system are now essential tools for any procurement professional purchasing respiratory protection.
FDA medical device oversight for PPE. The Food and Drug Administration issued and subsequently withdrew numerous Emergency Use Authorizations for PPE categories including respirators, surgical masks, and isolation gowns during the pandemic. The withdrawal of those EUAs has returned the market to pre-pandemic regulatory standards, but the experience highlighted gaps in FDA's oversight of imported medical PPE. Ongoing regulatory discussions continue to address how surgical mask and gown standards should be strengthened and harmonized.
ASTM and AAMI standards evolution. The American Society for Testing and Materials and the Association for the Advancement of Medical Instrumentation, which govern performance standards for medical gowns and protective apparel, have both engaged in standards review processes influenced by pandemic-era findings. Healthcare facilities should ensure that their gown and protective apparel specifications reference current editions of ASTM F3352 and ANSI/AAMI PB70 rather than legacy versions.
Emerging domestic certifications. The pandemic accelerated investment in domestic PPE manufacturing and, with it, increased interest in certifications and sourcing designations that distinguish American-made products. While no single federal "Made in USA" certification exists specifically for medical PPE, procurement professionals are increasingly attentive to manufacturing location as a supply chain risk factor.
The Domestic Sourcing Shift: Real Progress, Remaining Gaps
Perhaps the most structurally significant change since 2020 is the genuine, if incomplete, shift toward domestic PPE manufacturing.
Federal investment through programs including BARDA (Biomedical Advanced Research and Development Authority) and the Defense Production Act supported the establishment and expansion of domestic N95 manufacturing capacity. Companies that had no prior history in respiratory protection entered the market with domestic production capability. By 2023, domestic N95 manufacturing capacity had expanded substantially from its pre-pandemic baseline.
The picture for other PPE categories is more complicated. Medical gown manufacturing remains heavily concentrated offshore, with the domestic supply chain representing a modest fraction of total US consumption. Nitrile glove manufacturing, dominated by Malaysian producers, has seen some domestic investment but nothing approaching supply independence. Surgical mask manufacturing has diversified somewhat but remains significantly dependent on Asian supply chains.
For healthcare procurement professionals, the practical implication is this: domestic sourcing is now a realistic option for certain critical categories, particularly respiratory protection, but it is not yet a comprehensive solution. A procurement strategy that incorporates domestic sourcing for the highest-criticality items while maintaining diversified international supplier relationships for others represents the most defensible current approach.
What Hospitals and Clinics Should Reassess Right Now
Given the changes described above, healthcare facilities of all sizes should be conducting a structured reassessment of their PPE procurement strategy. The following areas warrant particular attention.
Supplier verification. The pandemic demonstrated that not all suppliers claiming to offer certified PPE actually deliver it. Healthcare facilities should require documentation of current certifications — NIOSH approval numbers for respirators, FDA 510(k) clearance or EUA status for applicable medical devices, ASTM compliance documentation for gowns — and should verify those documents independently rather than accepting them at face value. First Call PPE maintains full certification documentation for all products in our medical-grade catalog, available upon request.
Surge inventory planning. The just-in-time model is not appropriate for critical protective equipment. Healthcare facilities should establish minimum stockpile levels for essential PPE categories based on their patient volume and a defined surge scenario — typically a 30- to 90-day supply of highest-criticality items. This inventory should be actively managed with rotation protocols to prevent expiration.
Supplier diversification. Single-source dependency for any critical PPE category represents an unacceptable risk in the current environment. Facilities should maintain active relationships with at least two qualified suppliers for each major category, with pre-negotiated terms that can be activated rapidly in response to supply disruptions.
Staff training on proper use. Equipment that is not used correctly provides diminished or no protection. Post-pandemic research has reinforced the importance of training healthcare workers in proper donning, doffing, and disposal procedures, particularly for respiratory protection. Procurement decisions should account for whether the products selected are ones that staff can reliably use correctly under operational conditions.
An Honest Assessment of Where the Industry Stands
The healthcare PPE sector in 2024 is meaningfully better positioned than it was in February 2020. Standards have been strengthened, domestic capacity has grown, and procurement professionals have developed a more sophisticated understanding of supply chain risk. These are genuine improvements.
But the structural vulnerabilities that the pandemic exposed have not been fully resolved. Supply chains for several critical categories remain heavily concentrated in regions vulnerable to geopolitical disruption. Counterfeit and substandard products continue to circulate in the market, particularly through less-vetted online channels. Many facilities, particularly smaller community hospitals and outpatient clinics, have not completed the procurement strategy reassessment that the pandemic made necessary.
The lesson of the pandemic, applied forward, is that resilience requires deliberate investment before the next crisis, not reactive scrambling during it. Healthcare facilities that treat PPE procurement as a strategic function — rather than a routine purchasing activity — will be better positioned to protect their personnel and maintain operations when the next disruption arrives.
First Call PPE works with healthcare facilities across the country to build procurement strategies grounded in verified product quality, supply chain transparency, and genuine readiness. Because in healthcare, as in emergency response, the time to prepare is always before the moment of need.
